Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

https://jlabs.jnjinnovation.com/quickfire-challenges/jlabs-nyc-quickfire-challenge#paragraph-5131 https://www.prnewswire.com/news-releases/johnson–johnson-innovation-opens-jlabs–nyc-in-collaboration-with-new-york-state-and-the-new-york-genome-center-300670313.html

New York City, New York Feb 23, 2021 (Issuewire.com)  – Manhattan BioSolutions, Inc, an emerging biotechnology company focused on the discovery of immunoregulatory therapies […]

Collaboration with National Institutes of Health and Binghamton University to Develop Novel Antibody-Drug Conjugates for Pediatric Cancer New York City, New York […]